Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222670 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
A Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses, sponsored by ENA Respiratory Pty.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,100
- Enrollment target
- 5
- Study locations
NCT07222670 is a Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses that is actively recruiting participants, run by ENA Respiratory Pty. The registered enrollment target is 1,100 participants. The trial reports 5 study locations across 2 states.
The verdict
NCT07222670, a Phase 2 study of Viral Respiratory Infection and Viral Respiratory Illnesses, is actively recruiting participants, sponsored by ENA Respiratory Pty.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,100 participants
- Enrollment target
- 5
- Study locations
Study Summary
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG INNA-051
Study Locations (5)
North Carolina
- Accellacare of Raleigh - Raleigh
- Accellacare of Piedmont HealthCare - Statesville
- Accellacare - Wilmington - Wilmington
Maryland
- Center for Vaccine Development and Global Health (CVD) - Baltimore
- Naval Medical Research Command (NMRC) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2027-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222670
The ClinicalTrials.gov registry entry for NCT07222670 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ENA Respiratory Pty, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Viral Respiratory Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07222670 reports 5 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Maryland.
Frequently Asked Questions
What is clinical trial NCT07222670 about?
NCT07222670 is a clinical study titled "A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age". Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurr...
What is the current status of trial NCT07222670?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,100 participants. The study started on 2025-12-04. Estimated completion is 2027-02-09.
What conditions does trial NCT07222670 study?
This clinical trial studies the following conditions: Viral Respiratory Infection, Viral Respiratory Illnesses.
What interventions are being tested in trial NCT07222670?
The interventions under investigation include: Placebo (OTHER), INNA-051 (DRUG).
Who is sponsoring clinical trial NCT07222670?
This trial is sponsored by ENA Respiratory Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222670 being conducted?
This trial has 5 study locations across Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.